Beta-Blockers Following MI: Still Needed?

Overview

A recent meta-analysis published in JAMA Cardiology found that beta-blocker therapy does not improve cardiovascular outcomes in patients with preserved left ventricular ejection fraction after myocardial infarction. This challenges previous assumptions about the benefits of beta-blockers in this population.

Background

The management of myocardial infarction (MI) has evolved significantly, raising questions about the ongoing role of beta-blockers in patients with preserved left ventricular ejection fraction (LVEF). Current guidelines recommend beta-blocker use, but their long-term necessity in patients with preserved LVEF is now under scrutiny. Specific guidelines should be referenced to support this claim.

Data Highlights

The meta-analysis included data from four randomized clinical trials (REDUCE-AMI, CAPITAL-RCT, REBOOT-CNIC, and BETAMI–DANBLOCK) with nearly 20,000 patients, showing no significant differences in all-cause mortality, cardiovascular mortality, recurrent myocardial infarction, heart failure, or unplanned revascularization between those treated with beta-blockers and those who were not.

Key Findings

• Beta-blocker therapy did not reduce all-cause or cardiovascular mortality in patients with preserved LVEF post-MI.
• Rates of recurrent myocardial infarction, heart failure, and unplanned revascularization were similar between treatment groups.
• The findings contrast with earlier studies suggesting benefits of beta-blockers in patients with mildly reduced ejection fraction.
• Advancements in MI care, including early percutaneous coronary intervention and the use of other evidence-based therapies, may contribute to the lack of benefit from beta-blockers.
• The meta-analysis relied on aggregate data, limiting subgroup analysis and assessment of time-dependent effects, raising concerns about selection bias.
• Current guidelines recommend reassessing beta-blocker therapy beyond one year in patients with LVEF >50% without ongoing symptoms.

Clinical Implications

Clinicians should reconsider the routine continuation of long-term beta-blocker therapy in patients with preserved LVEF following myocardial infarction. Individualized treatment strategies may be necessary, considering alternative therapies and the evolving evidence and current guidelines.

Conclusion

The findings from this meta-analysis highlight the need for further research to clarify the role of beta-blockers in post-MI management for patients with preserved ejection fraction. Future studies should aim to identify specific patient populations that may still benefit from this therapy.

Related Resources & Content

1. K.-Y. Chi et al., European Journal of Preventive Cardiology, 2023 -- Beta-Blockers after myocardial infarction: returning from injured reserve
2. K.-Y. Chi et al., European Journal of Preventive Cardiology, 2023 -- Beta-blockers for secondary prevention following myocardial infarction in patients without reduced ejection fraction or heart failure: an updated meta-analysis
3. K.-Y. Chi et al., European Journal of Preventive Cardiology, 2023 -- Safety of beta-blocker discontinuation after acute coronary syndromes with preserved or mildly reduced left ventricular ejection fraction: a target trial emulation from a real-world cohort
4. Drugs - Real World Outcomes, 2016 -- Early Beta-Blocker Treatment Post-Myocardial Infarction: A Comparison of Discharge Medications Versus Pharmacy-Filled Prescriptions
5. ACC/AHA Task Force on Clinical Practice Guidelines, 2023 -- 2023 Chronic Coronary Disease guideline slide set
6. NEJM, 2024 -- REBOOT program findings
7. ACC/AHA Task Force on Clinical Practice Guidelines
8. The new engl and jour nal of medicine
9. https://mediacenteratypon.nejmgroup-production.org/NEJMoa2512686.pdf